Role of hematopoietic stem cell transplantation in relapsed/refractory hodgkin lymphoma

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 4, Issue 1, 2012, Pages

  Carella, Angelo Michele ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; CARMUSTINE; CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN; PANOBINOSTAT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REVIEW; SALVAGE THERAPY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84875974333     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2012.059     Document Type: Review

References (35)

1. Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report. J Clin Oncol 1988;6:1411-1416 PMid:2458439
2. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bonemarrow transplantation in relapsed and re-sistant Hodgkin's disease: results of a BNLI randomized trial. Lancet. 1993;341:1051-4. http://dx.doi.org/10.1016/0140-6736(93)92411-L
3. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002;359:2065-2070. http://dx.doi.org/10.1016/S0140-6736(02)08938-9
4. Yuen AR, Rosenber SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997;89:814-822. PMid:9028312
5. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 1999;17:222-229. PMid:10458237
6. Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, et al. Double high-dose therapy for Hodgkin's disease with dose intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2000;26:383-388. http://dx.doi.org/10.1038/sj.bmt.1702541 PMid:10982284
7. Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol. 2010;28:5074-80. http://dx.doi.org/10.1200/JCO.2010.30.5771 PMid:20975066
8. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol. 2005;16:1359-65. http://dx.doi.org/10.1093/annonc/mdi248 PMid:15939712
9. Josting A. Autologous transplantation in relapsed and refractory Hodgkin's disease. Eur J Haematol Suppl. 2005;66:141-145. http://dx.doi.org/10.1111/j.1600-0609.2005.00468.x
10. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, et al. High dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who fail to enter remission after induction chemotherapy: Results in 175 patients reported to the EBMT. J Clin Oncol. 1999;17:3101-3109. PMid:10506605
11. Constans M, Sureda A, Terol M J, Arranz R, Caballero MD, Iriondo A, Jarque I, et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Ann Oncol. 2003;14:745-51. http://dx.doi.org/10.1093/annonc/mdg206 PMid:12702529
12. Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A, Reman O, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Études des Lymphomes de l'adulte H89 trial. J Clin Oncol. 2002;20:467-75. PMid:11786576
13. Lazarus HM, Rowlings PA, Zhang M-J, Vose JM, Armitage JO, Bierman PJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999;17:534-45. PMid:10080597
14. Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T, et al. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplantation 2007;13:594-600. http://dx.doi.org/10.1016/j.bbmt.2007.01.072 PMid:17448919
15. Morschhauser F, Brice P, Fermè C, Diviné M, Salles G, Bouabdallah R, et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM Study Group. J Clin Oncol 2008;26:5980-5987. http://dx.doi.org/10.1200/JCO.2007.15.5887 PMid:19018090
16. Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, et al. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008;14:904-912. http://dx.doi.org/10.1016/j.bbmt.2008.05.021 PMid:18640574 PMCid:3353768
17. Constans M, Sureda A, Arranz R, Caballero MD, Carreras E, Conde E, et al. Relapse after autologous stem cell transplantation for Hodgkin's lymphoma: prognostic factors affecting long-term outcome. Eur J Haematol. 2004;73:53.
18. Martínez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, et al. Rewlapse of Hodgkin's Lymphoma after autologous stem cell transplantation (ASCT): Identification of prognostic factors predicting outcome. Blood. (submitted).
19. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007;109:2481-2489 http://dx.doi.org/10.1002/cncr.22714 PMid:17497648
20. Moskowitz AJ, Yahalom J, Kewalramani T, Maragulia JC, Vanak JM, Zelenetz AD et al. Pre-transplant functional imaging predicts outcome following autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. Blood 2010;116:4934-4937 http://dx.doi.org/10.1182/blood-2010-05-282756 PMid:20733154
21. Castagna L, Bramanti S, Balzarotti M, Sarina B, Todisco E, Anastasia A, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin Lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol 2009;145:369-372 http://dx.doi.org/10.1111/j.1365-2141.2009.07645.x PMid:19344403
22. Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff G, Pruim J, Vaalburg W, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurrent lymphomas. Blood. 2007;109:486-91. http://dx.doi.org/10.1182/blood-2005-11-006957 PMid:17003382
23. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000;25:345-350 http://dx.doi.org/10.1038/sj.bmt.1702204 PMid:10723575
24. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of Brentuximab Vedotin for patients with relapsed or refractory Hodgkin's Lymphoma. J Clin Oncol. 2012;30:2183-89. http://dx.doi.org/10.1200/JCO.2011.38.0410 PMid:22454421
25. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince M, et al. Panobinostat in patients with relapsed/refractory Hodgkin's Lymphoma after autologous stem cell transplantation: results of a phase II study. J Clin Oncol. 2012;30:2197-2203. http://dx.doi.org/10.1200/JCO.2011.38.1350 PMid:22547596
26. Robinson SP, Goldstone AH, Mackinnon S, Carella AM, Russell N, de Elvira CR, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310-4316 http://dx.doi.org/10.1182/blood-2001-11-0107 PMid:12393626
27. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, et al. Reduced-intensity allogeneic stem cell transplantationin relapsed and refractory Hodgkin's disease: lowtransplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005;35:943-51. http://dx.doi.org/10.1038/sj.bmt.1704942 PMid:15806128
28. Sureda A, Canals C, Arranz R, Caballero MD, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma: results of the HDR-Allo Study, a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Ósea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Leukemia. (submitted).
29. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, et al Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455-62. http://dx.doi.org/10.1200/JCO.2007.13.2415 PMid:18086796
30. Peggs KS, Thomson KJ, Hart DP, Geary J, Morris EC, Yong K, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103:1548-56. http://dx.doi.org/10.1182/blood-2003-05-1513 PMid:14576063
31. Peggs KS, Thomson KJ, Hart DP, Geary J, Morris EC, Yong K, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103:1548-56. http://dx.doi.org/10.1182/blood-2003-05-1513 PMid:14576063
32. Hart DP, Avivi I, Thomson KJ, Peggs KS, Morris EC, Goldstone AH, et al. Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions. Br J Haematol.2005;128:824-829. http://dx.doi.org/10.1111/j.1365-2141.2005.05388.x PMid:15755287
33. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, et al. Autografting followed by non-myeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000;18:3918-3924. PMid:11099321
34. Todisco E, Congiu AG, Castagna L, Nati ST, Santoro A, Carella AM. Tandem autologous/reduced-intensity allograft for relapsed/refractory Hodgkin's lymphoma: early allotransplant after intensive cytoreduction may maximize graft vs lymphoma effect? Haematologica 2009;94 (s2) abstr. 0090.
35. Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood. 2004;103:428-34. http://dx.doi.org/10.1182/blood-2003-05-1406 PMid:12969983